Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)
Giuseppe Lombardi, Paola Del Bianco, Alba A. Brandes, Marica Eoli, Roberta Rudà, Toni Ibrahim, Ivan Lolli, Simona Rizzato, Bruno Daniele, Andrea Pace, Francesco Pasqualetti, Mario Caccesse, Eleonora Bergo, Giovanna Magni, Gian Luca De Salvo, Vittorina Zagonel
Topics & Concepts
RegorafenibMedicineLomustineQuality of life (healthcare)Adverse effectInternal medicineClinical endpointClinical trialProgression-free survivalRandomized controlled trialCancerOncologySurgeryColorectal cancerOverall survivalChemotherapyCyclophosphamideNursingVincristineGlioma Diagnosis and TreatmentBrain Metastases and TreatmentMelanoma and MAPK Pathways